API Christmas everybody! - Top 10 API related developments in 2011

By Natalie Morrison

- Last updated on GMT

Related tags: Excipient, Active ingredient, Us

API Christmas everybody! - Top 10 API related developments in 2011
It’s been a busy year for API (active pharmaceutical ingredient) manufacturers with new facilities, cost pressures and regulatory developments all hitting the headlines.And it seems recent developments in HPAPIs (high potency APIs) have caused a stir with news of the industry taking up the top 4 places of our end-of-year run-down.Here are the most read API stories from in-PharmaTechnologist in 2011…

1. Indian Carbogen plant meets HPAPI handlingstandards

Carbogen Amcis' Indian plant received the regulatory thumbs up for the containment and handling of toxic APIs. Carbogen now handles all of Dishman’s HP API services.

2.Saltigo builds in HPAPI manufacturing space for US and Japanese customers

Saltigo announced plans to further its HPAPI business. Currently finishing up expansions in the US – due for ribbon cutting in early 2012 – the Frankfurt, Germany-based firm also received Japanese regulatory accreditation for its intermediates site.

3. Carbogen Amcis teams with liposomal delivery tech firm for HP API biz

It was a big year for Carbogen, with another HPAPI development when they inked a deal with Pulymun Scientific. The partnership, signed in October, granted Carbogen access to the Austrian firm’s liposomal formulation tech.

4. Roche cuts ribbon on new high potency facility

Instead of going down the production route, Roche opened the doors to its facility in New Jersey, US, to process high potency compounds into drugs. The factory now deals with tablets, capsules, powders, suspensions and solutions for preclinical studies as well as Phase I and II trials.

5. Granules to expand API and intermediate capacity

Indian chemical maker Granules announced plans to expand manufacturing capacity for oral solid dose APIs in August. The company predicts a boom in finished dosage demand over the coming years.

6. ScinoPharm goes public in preparation for expansion opportunities

Taiwanese API maker ScinoPharm took the business public in October in a bid to raise cash for upcoming expansions. The firm recently opened a plant in Changsu, Jiansgu in China and is planning more facilities in the next few years.

7. Costs ‘a burden’ for API excipient makers, says BASF after raising prices again

BASF made the headlines when it hiked the prices of APIs and excipients by 10 per cent twice in one year. The German chemical giant put the increase down to the rising costs of raw materials, energy and labour.

8. Round up of SAFC’s Glasgow conference

During a behind-the-scenes tour of its Glasgow plant, SAFC told in-PharmaTechnologist about its plans to focus on HPAPI production over the next year. The firm’s new aggressive growth strategy includes expansions in the US, Europe and developing markets.

9. Albemarle to hike generic API prices on regulatory costs

Another firm increasing its API prices was Abermarle, which announced that its generic ingredients would be more costly as of October 2011. The company said it was “investing for the future”​ of the quality of its products.

10. Joint FDA-EMA inspection program to launch in January 2012

And finally, the FDA and EMA decided to team up on facility inspection and have agreed to share data and duties from January 2012. The new collaboration was years in the pipeline, and follows recent results​ which suggest the move will reduce the number of duplicate inspections.

Related news

Show more

Related product

The Effect of Tamping Force on Bi-Layer Tablets

The Effect of Tamping Force on Bi-Layer Tablets

JRS PHARMA | 15-Aug-2020 | Technical / White Paper

Formulation of bi-layer or multi-layer tablets enables the combination of two or more drugs that may be incompatible or maybe intended for delivery at...

Related suppliers

Follow us

Products

View more

Webinars